A carregar...
Phase II Chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions
BACKGROUND: In a previous phase II trial, we demonstrated that fenretinide 200 mg/day had limited activity in retinoid-refractory leukoplakia (34% response rate), possibly due to the lack of achievement of high serum levels which would be required to elicit retinoid-receptor independent apoptosis in...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4161148/ https://ncbi.nlm.nih.gov/pubmed/19139014 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-08-0100 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|